Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clovis Oncology has entered into an agreement with Pfizer to develop and commercialize Pfizer's PF-01367338 as both a monotherapy and in combination with chemotherapeutic agents for the potential treatment of selected cancer patients.
Subscribe to our email newsletter
PF-01367338, an oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, is currently in Phase 1/2 development for solid tumors.
The program is supplemented by two ongoing trials, currently using the IV formulation: a Phase 1/2 study in gBRCA breast and ovarian cancer and a Phase 2 study in the adjuvant treatment of triple negative breast cancer.
Clovis Oncology intends to replace the IV formulation with the oral formulation in these studies.
Under the terms of the agreement, Pfizer will receive an upfront license fee payable in equity in Clovis Oncology and will be eligible to receive further payments totaling up to $255m upon Clovis Oncology’s successful attainment of development, regulatory and sales milestones.
Pfizer will also receive royalties on any product sales.
In addition, Pfizer Venture Investments, the venture capital arm of Pfizer, will make a separate equity investment in Clovis Oncology.